of all aspects of the center and/or mobile operations; interviews and carries out phlebotomy of blood donors; maintains blood donor … in interviewing and phlebotomy of donors, as required. Assists in preparing the unit of blood moving to processing … Learn More
Dr. Anthony Fauci responded to criticism from South Dakota Governor Kristi Noem on Sunday, after the Republican state leader suggested that her approach to COVID-19 mitigation was effective despite its obvious departures from the expert’s advice.
During an appearance on CBS News’ Face the Nation, Fauci encouraged Noem to “take a look at the numbers,” as South Dakota records some of the most significant increases in COVID-19 cases and deaths per capita in the country.
As longstanding director of the National Institute of Allergy and Infectious Diseases (NIAID), Fauci is an experienced public health specialist who helped guide the U.S. through COVID-19 mitigation as a leading member of Donald Trump‘s Coronavirus Task Force. He now serves as chief medical adviser to President Joe Biden.
“You know, it’s unfortunate…it is not really helpful,” he told moderator Margaret Brennan, referencing Noem’s remarks during a speech at this year’s Conservative Political Action Conference (CPAC) on Saturday, when she claimed that Fauci is “wrong a lot” during a speech that earned her a standing ovation.
“Because sometimes you think things are going well, and just take a look at the numbers. They don’t lie,” Fauci continued. “We see, Margaret, what happens when you pull back prematurely. Now, you’re going to have individual instances of situations where people may not have, and didn’t see a rebound right away. But you’ve really got to be careful, particularly now that we have variants in this country that seem to spread more efficiently and maybe even are more dangerous with regard to pathogenicity.”
Noem’s lenient approach to COVID-19 mitigation has been criticized throughout the pandemic. Unlike other states where leaders implemented mask mandates and restricted business operations in efforts to curb transmission, the Republican governor declined to effect orders stipulating public use of face coverings and largely shied away from regulating business activity.
“We never focused on the case numbers. Instead, we kept our eye on hospital capacity,” said Noem during Saturday’s speech at CPAC. “Now Dr. Fauci, he told me that on my worst day, I’d have 10,000 patients in the hospital. On our worst day, we had a little over 600. Now, I don’t know if you agree with me, but Dr. Fauci is wrong a lot.”
Data recently updated by the Centers for Disease Control and Prevention (CDC) indicates that South Dakota recorded the country’s eighth-highest number of COVID-19 deaths per capita over the past seven days, behind New York, New Jersey, Rhode Island, Massachusetts, Mississippi, Arizona and Connecticut. Its seven-day increase in confirmed cases, per 100,000 residents, came second only to North Dakota, which reported fewer fatalities last week as it has, overall, throughout the pandemic.
Leading national health expert Dr. Anthony Fauci criticized South Dakota Governor Kristi Noem’s response to COVID-19 as case numbers and related deaths continue to increase across the state. In the photograph above, Fauci speaks as White House Press Secretary Jen Psaki listens during a White House press briefing on January 21, 2021 in Washington, D.C. Alex Wong/Getty
Fauci acknowledged that COVID-19 numbers are declining across the country at the end of February, following a marked surge around the holiday season. However, he stressed that continued compliance with safety measures is necessary to further the downward trend, especially given the emergence of variant strains.
“Go back and look, historically, at what happened when we tried to open up the economy and open up the country,” he said. “And we saw a variable degree of adherence to the public health measures by different governors and different mayors. And what did happen? [The curve] went like this and then went right back up when we had yet again another surge.”
Noem defended her stance on COVID-19 mitigation, which calls on residents to exercise personal responsibility rather than abide by state mandates, during a later appearance on Face the Nation Sunday.
.@govkristinoem responds to Dr. Fauci’s warnings against COVID complacency:
“You indicated I ignored medical advice, and I didn’t listen to my health experts. I most certainly did,” she doubles down in interview with @margbrennan, adding her state took the virus “very seriously” pic.twitter.com/CUxR1SaQhK
“You indicated that I ignored medical advice, I didn’t listen to my health experts, and I most certainly did,” she said, addressing Fauci’s earlier comments. “In South Dakota, we took this virus very seriously. What I did, though, was tell my people the truth. I gave them personal responsibility over decisions for their families’ public health, but I also gave them the flexibility they needed to keep their businesses open, take care of their employees and their customers.”
Newsweek reached out to Noem’s office for comment, but did not receive a reply in time for publication.
Newsweek, in partnership with NewsGuard, is dedicated to providing accurate and verifiable vaccine and health information. With NewsGuard’s HealthGuard browser extension, users can verify if a website is a trustworthy source of health information. Visit the Newsweek VaxFacts website to learn more and to download the HealthGuard browser extension.
Enlarge/ A sign at the Johnson & Johnson campus on August 26, 2019 in Irvine, California.
UPDATE, February 27, 2021 7: 20 pm EST: The US Food and Drug Administration on Saturday evening granted emergency use authorization for Johnson & Johnson’s COVID-19 vaccine. The vaccine is the third authorized in the US and the first to require only a single shot, which can be shipped at refrigerator temperatures.
“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” acting FDA Commissioner Janet Woodcock said in an announcement.
The vaccine uses a non-replicating adenovirus (Ad26)—a type of virus that causes common colds—to deliver the genetic blueprints of the SARS-CoV-2 spike protein to cells. The FDA authorized it for use in people ages 18 and older.
“After a thorough analysis of the data, the FDA’s scientists and physicians have determined that the vaccine meets the FDA’s expectations for safety and effectiveness appropriate for the authorization of a vaccine for emergency use,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said. “With today’s authorization, we are adding another vaccine in our medical toolbox to fight this virus. At the same time, the American people can be assured of the FDA’s unwavering commitment to public health through our comprehensive and rigorous evaluation of the data submitted for vaccines to prevent COVID-19.”
Original story, February 26, 2021 5: 17 pm EST: After a day-long meeting Friday, an advisory panel for the US Food and Drug Administration voted 22 to 0 to recommend issuing an Emergency Use Authorization for Johnson & Johnson’s single-shot, refrigerator-stable COVID-19 vaccine.
If the FDA accepts the panel’s recommendation and grants the EUA—which it likely will—the country will have a third COVID-19 vaccine authorized for use. Earlier this week, FDA scientists released their review of the vaccine, endorsing authorization. Today’s panel, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) went through the data further.
“It’s a relatively easy call,” Eric Rubin, a Harvard researcher and voting member of the VRBPAC said after the vote. “[The vaccine] clearly gets way over the bar and it’s nice to have a single-dose vaccine… the demand is so large [for vaccines], it clearly has a place.”
Agency watchers expect the FDA to move quickly on the decision, possibly granting the EUA as early as tomorrow, February 27. The FDA moved that fast in granting EUAs for the two previously authorized vaccines, the Moderna and Pfizer/BioNTech mRNA vaccines.
Additionally, an advisory panel for the Centers for Disease Control and Prevention that makes recommendations on vaccine use has scheduled an emergency meeting for this Sunday to discuss the vaccine’s use, further bolstering speculation that the federal government will move quickly to authorize and roll out the vaccine. If all of the pieces fall in line, doses of Johnson & Johnson’s COVID-19 vaccine could begin shipping out to vaccination sites early next week.
The rollout won’t be a big burst of new doses right away, though; it will likely be a slow roll. In congressional testimony this week, a Johnson & Johnson executive said that the company would provide 4 million doses after the EUA, with a total of 20 million ready by the end of March and a total of 100 million by the end of June. Still, with the vaccine only requiring a single shot, those 100 million doses equate to 100 million people protected.
Efficacy
According to a detailed FDA review of Phase III clinical trial data submitted by Johnson & Johnson, the vaccine was 66 percent effective at preventing moderate to severe COVID-19 at 28 days after vaccination. (Johnson & Johnson defined moderate cases to include cases that had two symptoms, such as cough and fever, which would have been classified as simply “symptomatic” infections in other trials.)
The international trial, which involved over 44,000 participants in various trial sites, had different efficacies in different places. In the US, the overall efficacy was slightly higher, at 72 percent. But in places where variants of concern are widely circulating, the efficacy fell. It was 64 percent effective in South Africa, and 61 percent effective in Latin America.
Reassuringly, the efficacy against severe and critical disease was high across the board in all of the trial locations and across age groups. Efficacy against severe disease was 85 percent overall 28 days after vaccination. By location, efficacy against severe disease in the US was at 86 percent, 82 percent in South Africa, and 88 percent in Brazil. In a further analysis, there were zero hospitalizations among vaccinated participants and 16 in the placebo group. As of February 5, there were seven COVID-19-related deaths in the trial, all of which were in the placebo group.
In addition, Johnson & Johnson has a 30,000-person trial in progress testing whether adding a booster shot will further increase efficacy.
Side effects
As for side effects, the vaccine has a “favorable safety profile,” according to the FDA. The most common side effects seen among the 44,000 or so participants were injection site pain (49 percent), headache (39 percent), fatigue (38 percent), and myalgia (33 percent). There were 15 cases of blood-clotting-related conditions among vaccinated participants, compared with 10 in the placebo group. There were also six cases of tinnitus (ringing in the ears) among the vaccinated and zero in the placebo group. It’s unclear if these conditions were related to the vaccine.
While anaphylaxis has been a rare but documented occurrence with the mRNA vaccines, it appears to be less of a risk with Johnson & Johnson’s vaccine. There was a single case of a severe hypersensitivity reaction two days after vaccination that was considered likely related to the vaccine. But the reaction was not classified as anaphylaxis.
Center: LOC0028 – 30 Tank Park Drive30 Reservoir Park Drive Rockland, MA 02370 Department Call: OP Outreach Phlebotomy … Status: Part time Budgeted Hours: 0 Shift: Varied Shifts (United States of America) Carries Out phlebotomy functions … Find Out More
Summary of Position: Performs phlebotomy techniques to obtain blood specimens on patients of all ages. Interprets…. Assist in clerical functions of department. Minimum Qualifications: High school graduate or GED required. Prior phlebotomy… Read More
Mike Lindell, the founder and CEO of the MyPillow bedding company, spoke about coronavirus conspiracy theories with the Right Side Broadcasting News (RSBN), a conservative pro-Trump YouTube channel, at the Conservative Political Action Conference (CPAC) on Sunday.
In a video posted to Twitter by Bloomberg reporter William Turton, Lindell is shown sitting in a booth at the conference beside Right Side Broadcasting host Liz Willis.
At the beginning of the clip, Lindell claims that people who have not contracted COVID-19 are being diagnosed with the virus for nefarious reasons.
“You stub your toe, and they say ‘Oh, you’ve got COVID!” Lindell said.
However, before the CEO continued, he was interrupted by Willis.
“We do have to be super careful,” said Willis. “Due to YouTube’s guidelines, we will get our whole platform shut down if we talk about the vaccines.”
Mike Lindell, CEO of MyPillow, is here at CPAC. In this clip, he is spreading conspiracy theories about the coronavirus, and the Right Side Broadcasting host interrupts him to provide a disclaimer about the YouTube rules. pic.twitter.com/B8GCEY4Pbr
During his interview with Right Side Broadcasting, Lindell also mentioned that the prime minister of Israel is “making the whole country” take the COVID-19 vaccine.
“What do you care what someone else does,” Lindell said. “This is our bodies. This is ‘mark of the beast’ stuff.”
Lindell previously referred to the COVID-19 vaccine as the “mark of the beast”— a prophet mentioned in chapter 13, verse 18 of the biblical Book of Revelations—during a February 6 appearance on Steve Bannon’s War Room: Pandemic podcast.
“Now it’s this ‘one World Order,’ this stuff is in Revelations, you know that’s what I was talking about, and you combine that with this vaccine, that’s ‘mark of the beast’ stuff,” Lindell said. “I mean, this is horrible, keeping us indoors.”
The biblical verse has been interpreted in different ways throughout history.
Some Christians believe that the mark refers to a tattoo or branding marker that anti-Christians will impose on the world for the purpose of control. Other Christians believe that the mark symbolically means allegiance to a non-religious government.
MyPillow CEO Mike Lindell is shown above waiting outside the West Wing of the White House on January 15, 2021 in Washington, DC. He has since called the COVID-19 vaccine the “mark of the beast.” Photo by Drew Angerer/Getty Images/Getty
Lindell has also been a vocal proponent of election fraud conspiracy theories. An ally of former President Donald Trump, he has repeatedly claimed that Dominion Voting Systems, the company behind the voting machines used in the 2020 election, helped influence the election in favor of President Joe Biden.
Several stores, including Bed Bath & Beyond, Kohl’s, and Wayfair, among others, have stopped carrying MyPillow. Twitter has also banned the company and its CEO from the platform.
David Hogg, a Parkland High School shooting survivor and March for Our Lives Founder, announced a “progressive” pillow company on February 4 as a direct rival to Lindell’s pillow line.
Newsweek reached out to Lindell through MyPillow, but didn’t hear back in time for publication.
Make your busy days simpler with Axios AM/PM. Catch up on what’s new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider’s guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
NIAID Director Anthony Fauci. Photo: Win McNamee/Getty Images)
Children under age 12 will “very likely” be able to get vaccinated for coronavirus at the “earliest the end of the year, and very likely the first quarter of 2022,” NIAID Director Anthony Fauci told “Meet the Press” Sunday.
Why it matters: Children generally aren’t at risk of serious coronavirus infections, but vaccinating them will be key to protecting the adults around them and, eventually, reaching herd immunity, writes Axios’ Caitlin Owens.
The sooner children have a vaccine, the sooner schools and child care can go back to normal, which will greatly ease the burden on millions of parents.
“If you project realistically when we’ll get enough data to be able to say that elementary school children will be able to be vaccinated, I would think that would be, at the earliest, the end of the year,” Fauci said. “And very likely, the first quarter of 2022.”
Fauci added that high school kids should be able to get the vaccine “sometime this fall. I’m not sure it’ll exactly be on the first day that school opens, but pretty close to that.”
The Collaborative Assessment and Management of Suicidality (CAMS) approach has garnered a strong evidence base and has been implemented by therapists from a range of orientations in diverse clinical settings. This extensively revised manual provides a proven therapeutic framework for evaluating suicidal risk and developing and implementing a suicide-specific treatment plan that is respectful, empathic, and empowering. In addition to their clinical utility, the procedures used for assessment, treatment, and progress monitoring within CAMS can help reduce the risk of malpractice liability. In a large-size format for easy photocopying, the book includes all needed reproducible tools for implementing CAMS. Purchasers also get access to a Web page where they can download and print the reproducible materials. For CAMS training opportunities with David A. Jobes, visit www.cams-care.com. New to This Edition *Incorporates a decade’s worth of extensive clinical research. *Fully revised with a greater focus on CAMS as a framework for clinical intervention–not just assessment. *In-depth case example followed throughout the book. *Describes innovations to the approach, such as how to target and treat patient-defined “suicidal drivers.” *Additional reproducibles (CAMS Therapeutic Worksheet and CAMS Rating Scale), plus a new version of the Suicide Status Form.
The second edition of the textbook is planned to become a MRW-textbook. It will be written by 389 eminent pediatricians and scientists from leading university hospitals and health centers in North America, Europe, Asia and Australia. Written with more than 425 chapters, the book will encompass virtually all pediatric subspecialties, covering every pediatric disease and organ system. Its strong clinical focus with a problem based approach will help practicing pediatricians, residents, medical students as well as family practitioners to manage sick children in a practical way, based on scientific evidence. Thus, it will become a valuable reference and resource for all health care practitioners dealing with pediatric patients.
A health worker holds the Johnson and Johnson vaccine at the Chris Hani Baragwanath Hospital in Soweto in February 17, 2021.
Emmanuel Croset | AFP | Getty Images
The Food and Drug Administration has approved Johnson & Johnson‘s Covid-19 vaccine for emergency use, giving the United States a third tool to fight the pandemic as highly contagious variants start to take root across the country.
The FDA’s emergency use authorization Saturday kickstarts the federal government’s plan to distribute nearly 4 million doses of J&J’s vaccine to states, pharmacies and community health centers across the nation next week. Unlike Pfizer‘s and Moderna‘s vaccines, J&J’s one-dose regimen eliminates the need for patients to return for a second dose and it can be stored at refrigerator temperatures for months.
J&J’s vaccine “makes it operationally easier in lots of contexts,” Dr. Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, told the Journal of the American Medical Association during a Q&A event on Friday. “I expect lots of considerations state health departments are having around these vaccines is more about the ease of use of the J&J vaccine and how it might be better suited for some populations.”
Initially, doses would be limited, J&J has said. The company expects to deliver 20 million doses by the end of March, J&J’s vice president of U.S. medical affairs, Dr. Richard Nettles, told House lawmakers on Tuesday. J&J has a deal with the U.S. government to supply 100 million doses of its vaccine by the end of June, and U.S. officials say they are working with the company to ramp up supply as quickly as possible.
In recent weeks, U.S. health officials have pushed Americans to get vaccinated as quickly as possible. Officials are growing concerned about new, emerging variants of the virus, particularly the B.1.351 strain, which has been shown to reduce the effectiveness of vaccines both on the market and under development. On Friday, the head of the Centers for Disease Control and Prevention, Dr. Rochelle Walensky, warned the declines in Covid-19 cases reported in the U.S. since early January may be flattening as variants spread.
J&J submitted its Covid vaccine data to the FDA on Feb. 4. The vaccine’s level of protection varied by region, J&J said, with the shot demonstrating 66% effectiveness overall, 72% in the United States, 66% in Latin America and 57% in South Africa, where the B.1.351 variant is rapidly spreading. However, FDA documents show the vaccine was 64% effective in South Africa after about a month. The company said the vaccine prevented 100% of hospitalizations and deaths.
Pfizer’s vaccine was found to be 95% effective against preventing Covid-19, while Moderna’s was found to be about 94% effective. Infectious disease experts pointed out that J&J’s numbers can’t be used as a direct comparison to the other two vaccines because it’s a single dose and the company’s trial was conducted when there were more infections as well as new, more contagious variants.
The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.
The FDA authorized J&J’s vaccine for people who are 18 years old and older. It isn’t the same as full approval, which requires more data and can typically take several months longer. J&J, like Pfizer and Moderna, has submitted only two months of safety data, but the agency usually requires six months for full approval. The FDA approved the emergency use of hydroxychloroquine to treat Covid-19 in March, only to revoke it in June after additional data showed it provided “no evidence of benefit” in coronavirus patients.
The FDA was expected to approve J&J’s vaccine for emergency use.
The agency’s announcement comes after a key panel on Friday unanimously backed the vaccine for emergency use The FDA’s Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.
After the vote, Dr. Archana Chatterjee, an infectious disease expert at Chicago Medical School and a voting member of the committee, said J&J’s vaccine will help “meet the needs of the moment” as states complain there is not enough supply of Pfizer’s and Moderna’s vaccines.
“We need to get this vaccine out now,” Dr. Jay Portnoy, a professor UMKC School of Medicine and a voting member of the committee, said after the vote. He added, “we’re in a hurry” as the variants pose a threat to the nation’s progress on the pandemic.
No specific safety concerns from J&J’s vaccine were identified. Headaches, fatigue and muscle pain were some of the most common side effects among people who received the inoculation, according to an FDA report published Wednesday. There were also reports of nausea, fever and pain at the injection site, the report said.
Macaya Douoguih, head of clinical development and medical affairs for J&J’s vaccines division Janssen, told the FDA panel on Friday that two people suffered severe allergic reactions shortly after getting the vaccine. One of the people was participating in an ongoing trial in South Africa and developed anaphylaxis, a severe and life-threatening allergic reaction.
The company has said it plans to ship the vaccine, which contains five doses per vial, at 36 to 46 degrees Fahrenheit. By comparison, Pfizer’s vaccine needs to be stored in ultra-cold freezers that keep it between minus 112 and minus 76 degrees Fahrenheit, though the FDA recently allowed the company to store its vaccine for two weeks at temperatures commonly found in pharmaceutical freezers. Moderna’s vaccine needs to be shipped at 13 below to 5 degrees above zero Fahrenheit.
Licensed Phlebotomy Professional (CPT/PBT) Job ID 2020-4007 Job Locations US-MS-Etta Published Date 2 months ago(12/29 … sufficient materials for phlebotomy procedures & alert supervisorial staff for orders to guarantee no disruption in typical … Find Out More
Learn about the external anatomy of the heart and the coronary arteries. Presented in a clear way, this lesson is helpful for students and patients wanting to gain a higher understanding of how oxygenated blood is distributed to the heart’s muscle tissue. This lesson is presented for educational and instructional functions just. This lesson does not satisfy the requirements for certification. Students wanting to achieve accreditation needs to go to a licensed school and finish the program requirements.
Misinformation runs rampant online, even from my colleagues in the health care industry. We need to do better.
Social media platforms have been instrumental in allowing misinformation and distrust to proliferate, hindering the fight against the COVID-19 pandemic as well as contributing to deeply cut social and political divides, and an insurrection on the Capitol.
As a community nurse in and around Chicago, I have been personally and professionally thrust into the role of social media fact checker for my patients. I live in the intersection between health care, science, and a misinformed public.
I don my often-painful N95 mask, tie my hair back, and evaluate patients every day. I field patient questions about microchipped syringes, and offer overly-simplified explanations about the bureaucratic logistics of scientific research and vaccine development. In moments I attempt to educate patients on cell biology, immunology, and microbiology — subjects I’ve taken years to study.
While cases and hospitalization of COVID-19 patients have dropped significantly around the country, the threat of infection remains an ever-present reality. Public confidence in the COVID-19 vaccine is improving, but not improving fast enough.
A new poll by the Kaiser Family Foundation found that of those who were surveyed, 44% expressed vaccine hesitancy and among that group, social media was cited as a main source of vaccine information. The poll also found only 31% of respondents said they get “a fair amount of information” from nurses, doctors, and other health care providers. While patient education is a central tenant of a nurse’s job, the rampant spread of misinformation and conspiracy theories have made the task more difficult.
Fueling fear and doubt
Recent news demonstrates nurses and doctors are not immune to misinformation. Last December, an Oregon doctor’s license was suspended for refusing to wear a face mask. Just last month, four nurses in Kansas refused to administer the vaccine, citing misinformation as justification for their refusal. These types of actions from trusted medical professionals have only fueled public fear and doubt.
While misinformation remains pervasive in its most nefarious forms online, more innocuous inaccuracies have flourished, too. My Instagram feed is filled with stories and posts from my health care worker friends and colleagues promoting vaccine acceptance and Centers for Disease Control and Prevention guidelines. My colleagues, many of whom have pursued rigorous years of study and training to become health care workers, frequently repost attractive, clean-lined, millennial-art styled infographics on health promotion and the dangers of COVID-19.
But in the summer of 2020, while swiping through Instagram, I noticed one infographic posted by a nurse colleague. It featured six stylized images of masked and unmasked faces; each face featured a percentage of COVID-19 transmission risk depending on the mask combination. My immediate impulse was to repost it, but the percentages written on the image didn’t seem accurate, so I decided to dig deeper. It took one quick Google search to realize that these percentages — while well-intended — had not been verified.
Studies around health misinformation have often concluded that fear, anxiety and risk perception sway individuals to make instinctive, autonomic decisions about their health and self-protection. The ease with which healthcare workers can unthinkingly repost and retweet self-affirming health content is enticing, and therefore, extremely dangerous.
For this reason, state medical boards across the nation are taking an active role in impeding misinformation or CDC guideline violations by physicians and other providers with penalty of revoking their license. For instance, at least one hospital forced administrative leave on a nurse who actively flout social distancing guidelines on social media.
Health care workers, do your part
Fear of professional retribution should not be the only thing stopping health care workers from spreading lies and misinformation. In the context of this global pandemic, reposting health misinformation on a whim can be especially dangerous for a trusted medical professional to do.
Whether fair or not, the reality of being a health care worker is to be trusted to make the best decisions for the health of the community, both in our private and public lives. Reposting inaccurate information on social media, no matter how seemingly harmless, can erode public trust and professional credibility.
There are many resources that exist to do just that, including step-by-step guides on how to distinguish fact from fiction. Among other strategies to recognize fake news, check for spelling errors or consider the information’s effort to appeal to emotions.
It is not uncommon for a friend or family member to connect with me on social media to ask for my medical opinion. I’ve answered questions ranging from what is appropriate footwear for back pain, to precautions to take if someone in the household has been diagnosed with COVID-19.
For better or for worse, social media has the potential to intertwine private and professional lives. For this reason, nurses, doctors, and other health care workers must truly scrutinize health information that they perpetuate online.
This is more than a caveat to think before you post.
The ability to discern what is and isn’t credible on social media is a necessary tool for navigating today’s digital world. Understanding the gravity of misinformation is the crucial first step in establishing personal and professional accountability for what is posted online.
For a health care worker, failure to fact check a post on social media can not only result in professional penalties, but can also mean life or death.
Katherine Buaron, RN, has a Master of Science in Nursing and is a community health registered nurse at Rush University Medical Center in Chicago and a Public Voices Fellow with The OpEd Project
Read or Share this story: https://www.usatoday.com/story/opinion/voices/2021/02/28/health-care-covid-19-news-fake-misinformation-column/6828004002/
Scamming has skyrocketed in the past year, and much of the increase is attributed to COVID-related scams, more recently around vaccines.
Why it matters: The pandemic has created a prime opportunity for scammers to target people who are already confused about the chaotic rollouts of things like stimulus payments, loans, contact tracing and vaccines. Data shows that older people who aren’t digitally literate are the most vulnerable.
Driving the news: New data from the Federal Trade Commission — which oversees consumer fraud and deception cases — finds that in 2020, the FTC received more than 4.7 million reports around scams from consumers, up from 3.2 million in 2019.
The agency received more than 2.2 million reports about fraud specifically, totaling $3.3 billion in consumer losses.
An overwhelming number of scams target older people, the FTC data suggests, with 60 to 69 year olds reporting losses of more than $56 million to coronavirus frauds.
Most COVID-related fraud reports are attributed to online shopping scams, which is notable given the uptick in e-commerce during the pandemic.
The Department of Homeland Security has analyzed nearly 80,000 COVID-19 domain names in its pursuit of scams.
In a blog post, the agency notes it has made 227 arrests, served 222 criminal search warrants and opened 862 investigations related to COVID scams.
As of Feb. 10, Homeland Security agents have seized more than $33 million in illicit proceeds attributed to COVID-19 scams selling counterfeit N95 masks.
Breaking news events have long been an opportunity for scammers to act, in an effort to capitalize on existing confusion.
For example, the data shows that there was a massive increase in identify theft scams the day of and the day after the Capitol insurrection on Jan. 6.
The FTC found that imposter scams — where the perpetrators disguise their identities, usually as government officials — were the most common type of scam last year.
“Government and business imposter scams were also among the top categories of COVID-19 and stimulus related reports, proving once again, that scammers follow the headlines,” an agency official wrote in a blog post.
The big picture: While social media is often thought of as the murkiest part of the internet, most scammers aren’t using social media to trick consumers, as the biggest platforms has gotten very good at weeding out bots and scam accounts.
Rather, the vast majority of scams, including COVID-19 scams, are occurring via phone calls, texts and emails.
The FTC found that there was a sharp increase in the number of text message scam reports last year. Many of the text messages were related to the pandemic, as well as other topics like stimulus relief or loans.
Facing a deluge of 365,000 reports and counting, the FTC has fired off more than 350 “warning letters” to companies related to potential coronavirus pandemic scams.
The letters are a way for the agency to quickly prod companies into taking down problematic claims, FTC attorney Christine DeLorme told Axios, adding that they have a high compliance rate.
“We think that is an incredibly good use of our resources to send a warning letter, if we can get those claims stopped in a matter of days,” she said..
More broadly, federal agencies are trying to educate consumers.
The Federal Communications Commission on Friday held a webinar aimed at helping older people avoid vaccine-related robocall and robotext scams, while the FTC is holding a cyber scams event with AARP and the Consumer Financial Protection Bureau on March 4.
For people wondering how to avoid being scammed during this period of unprecedented uncertainty, the government offers a few tips:
Anyone calling from a number you do not know asking for information about your health insurance, Social Security number or financial information are likely scammers.
People soliciting payments to help you with things like health care or vaccine enrollments are likely scammers, as those are services the government offers for free.
Scammers will often pretend to be organizations you are familiar with. It’s for this reason, as Axios has previously reported, that scam callers will often spoof D.C.-area codes pretending to be government bodies, like the IRS or HHS.
An updated and broadened edition of a college survival primer by two college teachers shares necessary guidance and strategies on subjects ranging from tension management and test preparation to staying inspired and balancing academics with a social life. Original.
Designed to fulfill the requirements of both clinical laboratory technicians and clinical lab researchers, this thorough – yet easy to check out – guide to hematology and hemostasis features cutting-edge innovations, top quality photos and micrographs, case studies, and practical dual-level (standard and sophisticated) discussion of details. In each chapter, 2 levels of objectives and questions are presented, enabling material to fit particular course focus. Case research studies and checkpoints in each chapter assistance apply and assess understanding. Visual cross-referencing signs throughout make finding info extremely easy. Features: Reliable material from 24 factors. Running case research studies throughout each chapter. “Checkpoints “- concerns, incorporated throughout the chapter, with reasonings supplied. High-resolution, full-color blood and bone marrow pictures throughout. COMPLIMENTARY CD-ROM includes a powerful database of images and self-assessment activities. FREE incorporated website – www.prenhall.com/mckenzie – compliments the text with study-guide design quiz concerns and instant tabulation of test outcomes. Detailed conversations of ethical concerns and management problems. The new innovations of molecular diagnostics, flow cytometry and cytogenetics provided here in an extremely quickly understood way.
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
The award of a new government contract to data analytics supplier Palantir on the back of its participation in the NHS Covid-19 data store has provoked Open Democracy into legal action, backed up by an exposure of lobbying activity that pre-dates the pandemic
Media organisations Open Democracy and the Bureau of Investigative Journalism have acted in unison to put in question the NHS and the UK state’s wider dealings with data mining company Palantir.
The Palo Alto-based firm was co-founded by leading Silicon Valley venture capitalist Peter Thiel in 2003. And although its co-founder and CEO, Alex Karp, is a self-described socialist, the company’s client base in the CIA and the FBI has made it controversial among civil libertarians.
In March 2020, the NHS confirmed it was working with Palantir, Microsoft and Google to improve its data analytics efforts and make its battle against the Covid-19 coronavirus more efficient and effective. From that work emerged the NHS Covid-19 Data Store.
NHS England’s web page on the store describes it like this: “The NHS Covid-19 Data Store sits on a Microsoft Azure platform under contract with NHS England and NHS Improvement. Within that secure cloud processing environment, Palantir (acting under instruction from NHS England) manage their platform which is called Foundry.
“Palantir have built analytical dashboards for access by NHS England and Improvement staff, together with staff in the following organisations working under contract: Faculty AI, McKinsey and Deloitte. Data which is pseudonymised is only available to staff working under contract with the organisations operating jointly under the NHSX banner. Palantir does not store the data itself, which remains under the control of the NHS.”
While it was reported, in March 2020, that NHSX and NHS England’s technical teams had built a back-end data store on Microsoft’s cloud platform, Azure, to “bring multiple data sources into a single, secure location”, it was Palantir Technologies UK that would provide the software, Palantir Foundry, that constitutes the front-end data platform. Palantir Foundry is said to enable disparate data to be cleansed and integrated.
“We’re taking the government to court because, right before Christmas, they quietly gave CIA-backed firm [Palantir] a major, long-term role in handling our personal health information, and in England’s cherished National Health Service” Open Democracy
Open Democracy has now initiated legal proceedings against the UK government for extending the “emergency” and virtually pro bono (a nominal cost of £1) contract struck with Palantir at the height of the first wave of the Covid-19 pandemic. The new contract, signed in December 2020, objects Open Democracy, is for two years and “reaches far beyond Covid: to Brexit, general business planning and much more”. The contract’s value for “data management platform services” is £23.5m.
Meanwhile, the Bureau of Investigative Journalism has published a related story detailing lobbying by Palantir among senior NHS executives that pre-dates the coronavirus crisis and reaches back into 2019.
The Open Democracy organisation said, in a statement explaining why it is suing the government: “We’re taking the government to court because, right before Christmas, they quietly gave this CIA-backed firm a major, long-term role in handling our personal health information, and in England’s cherished National Health Service.”
Meanwhile, the Bureau of Investigative Journalism has revealed that Palantir’s UK boss, Louis Mosley, hosted a dinner attended by David Prior, chair of NHS England, on 2 July 2019. The bureau cited an email of which it has gained sight, in which Prior said: “Louis, thank you for hosting such an interesting dinner and also for the watermelon cocktails! If you can see ways where you could help us structure and curate our data so that it helps us deliver better care and provides a more insightful database for medical research do be in touch.”
As reported by the BBC, the legal case, which is being handled by law firm Foxglove on behalf of its client Open Democracy, turns on whether a fresh Data Protection Impact Assessment is required for the new contract.
“The government shouldn’t use the pandemic as an excuse to embed major tech firms like Palantir in the NHS without consulting the public, Foxglove director Cori Crider told the BBC.
“The datastore is the largest pool of patient data in UK history. It’s one thing to set it up on an emergency basis, it’s a different kettle of fish to give a tech firm like Palantir a permanent role in NHS infrastructure.”
Sky News cited an NHS spokesperson as saying: “The company is an accredited supplier to the UK public sector. The NHS completed a Data Protection Impact Assessment in April 2020, and an update will be published in due course.”
Palantir is not commenting on the story.
Content Continues Below
Read more on Artificial intelligence, automation and robotics
Position Summary The Lead Inpatient Phlebotomy Tech interacts with patients, visitors, and other health care… Inpatient Phlebotomy Tech is proficient in all areas of phlebotomy and leads the department by their example. He/she serves… Read More
Lake Jackson, TX Order: 1925036 Order Type : Temp Phlebotomy Position Available NOW! Looking for a new… Job Requirements: Collecting Specimens in a lab is required. Must have great phlebotomy and customer service skills. Benefits… Read More
BRUSSELS (Reuters) – German Chancellor Angela Merkel said the European Union must prepare to vaccinate for new COVID-19 variants over the coming years after EU leaders discussed ways of stepping up innoculations and salvaging businesses, including tourism.
The 27 EU leaders agreed to keep “tight restrictions” on public life and free movement in place as the bloc races against the emergence of new variants that may hamper an economic rebound.
“We have to prepare for a situation where we have to continuously vaccinate for a longer period of time, maybe over years, due to new coronavirus variants, akin to the situation we know from the flu,” Merkel said.
The executive European Commission told the virtual leaders’ gathering that 51.5 million doses of vaccines had so far been delivered to the EU and 29.17 million administered, with about 5% of citizens having had their first dose, according to figures seen by Reuters.
The Commission and EU countries have come under fire for missteps in their joint inoculation programme and a stuttering rollout of shots that has lagged badly behind Israel, Britain and the United States.
Summit chairman Charles Michel said the bloc wanted “more predictability and transparency” from pharmaceutical companies that failed to deliver contracted vaccine volumes, putting at risk the EU’s target of innoculating 70% of its adult population by the end of the summer.
VACCINE CERTIFICATES
After the pandemic killed more than 900,000 people in Europe and thrust it into its worst-ever recession, EU leaders agreed to advance work on vaccine certificates, which southern countries hope will unlock tourism this summer.
But others, including France and Germany, are sceptical. Merkel said technical work on that should be completed by the summer.
As the EU treads a fine line between restrictions to stop the spread of infections and keeping borders open to ensure the smooth flow of goods and services across the single market, Merkel said she did not expect to impose tighter border restrictions on the French Moselle region for now.
Although infection rates are heading down in about 20 EU member states, there are concerns about fresh spikes as the coronavirus variant first detected in Britain spreads rapidly.
The head of the Commission, Ursula von der Leyen, said the British variant was present in 26 of the EU’s 27 countries, the South African variant in 14 and Brazilian in seven nations.
“There is growing COVID fatigue among our citizens… But we should not let up now. Not only does the situation remain serious in many parts of Europe but we must also watch for the new variants that are spreading,” she said.
Prime Minister Jacinda Ardern ordered New Zealand’s largest city back into lockdown on Saturday as COVID-19 cases continued to be detected in the community.
The latest restrictions in Auckland will last at least seven days and come less than two weeks after a three-day shutdown in the city.
Ardern said a new coronavirus case confirmed on Saturday could not be directly connected to other positive tests over the last two weeks, although a school in South Auckland was a common link.
From Sunday morning the city’s 1.7 million residents must stay at home except for essential shopping and work.
Schools and non-essential shops will close, and entry in and out of the city will be restricted.
The remainder of the country will be under level two restrictions which include limits on the size of public gatherings.
Ardern said there was “cause for concern” that the latest case involved a person who had been infectious for a week but had not been in isolation.
Since the latest outbreak first emerged in a family of three, several people have reported symptoms, with the school in South Auckland the connecting factor.
Ardern blamed the creeping spread of community infection on people not isolating when they should have been.
In the latest case the person visited a doctor on Friday and then went to the gym.
“It’s frustrating,” Ardern said.
Authorities have the ability to take enforcement action against rule breakers but that needed to be balanced with ensuring people with symptoms came forward, the prime minister added.
“We will always weigh up, are we creating an environment where people will be open and honest?” she said.
“We are dealing with young people here and what we ask them to do is share with us their entire lives, and it’s very important that we have a situation where people are able and willing to do that.”
New Zealand has been widely praised for its handling of the pandemic, with just 26 deaths in a population of five million.
Citation:
New Zealand’s largest city back in lockdown as COVID lingers (2021, February 27)
retrieved 27 February 2021
from https://medicalxpress.com/news/2021-02-zealand-largest-city-lockdown-covid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Half Round, Stationary, Padded Phlebotomy Stand, Royal Blue
Easy-clean plastic bin is ideal for saving phlebotomy products Chrome-plated steel pole with knob-lock change Five-leg, cast-aluminum base with nonmarking nylon glides ML20089 changes ML17084 Consists of a 10.75″ L x 8.25″ W x 3.5″ D plastic bin This discussion contains images that were used under an Innovative Commons License.
Easy-clean plastic bin is perfect for saving phlebotomy products Chrome-plated steel pole with knob-lock modification Five-leg, cast-aluminum base with nonmarking nylon glides ML20089 replaces ML17084 Includes a 10.75″ L x 8.25″ W x 3.5″ D plastic bin This presentation consists of images that were utilized under a Creative Commons License.
The House passed the latest stimulus bill, but what’s in the $1.9 trillion COVID relief package? What happens next and when will people see any money?
USA TODAY
WASHINGTON — The Democratically-controlled House approved President Joe Biden’s $1.9 trillion COVID relief package early Saturday, a key step for a measure that would provide millions of Americans $1,400 stimulus payments, ramp up vaccine distribution and extend unemployment aid through the summer.
The bill, known as the American Rescue Plan, passed 219-212. No Republicans voted for it, and two Democrats voted against it: Rep. Kurt Schrader, D-Ore., and Jared Golden, D-Maine.
The measure now heads to the Senate where it faces a rocky path in the evenly divided chamber.
No Senate Republicans are expected to support the bill, citing its size and scope, so the president will have to count on every one of the 50 Democratic senators — and a tie-breaking 51st vote from Vice President Kamala Harris — to make sure its key pillars remain in the bill.
“It’s a great day for us to take a vote to reduce the spread of this virus…put vaccinations in the arms of the American people, money into the pockets, children into the schools, workers back into their jobs, so that we can go forward,” House Speaker Nancy Pelosi said before the vote. “I salute President Biden for his American Rescue Plan.”
During brief remarks at the White House Saturday, Biden said he had just called Pelosi and thanked her for her “extraordinary leadership.”
The president said the House vote moved the country “one step closer” to “vaccinating the nation,” putting “$1,400 in the pockets of Americans, extending unemployment benefits, “getting our kids safely back in school,” and “getting state and local governments the money they need.”
He urged the Senate to “take quick action” to approve his relief plan.
“We have no time to waste. If we act now, decisively, quickly and boldly we can finally get ahead of this virus, we can finally get our economy moving again,” he said.
The bill passed by the House would:
Provide most Americans with another direct payment — this time for $1,400. (Republicans have proposed $1,000).
Extend federal bonus to unemployment benefits through August (the current benefit ends in mid-March) and bump up the amount to $400 per week. (Republicans want $300 a week through June).
Send $350 billion to state and local governments whose revenues have declined due to COVID social distancing measures (Republicans oppose any such “bailout”).
Allocate $130 billion to help fully reopen schools and colleges (Republicans are countering with $50 billion).
Allot $30 billion to help renters and landlords weather economic losses (Republicans oppose any amount).
Set aside $50 billion for small-business assistance (Republicans agree).
Appropriate $160 billion for vaccine development, distribution and related needs (Republicans also agree).
Biden and Democrats want the bill passed by mid-March, before the current unemployment insurance benefits provided in an earlier relief package expires.
Republicans have largely lined up in opposition to the plan. Rep. Tom Cole, R-Okla., derided it as a “bloated plan with unrelated policies.”
Though some support some elements of Biden’s proposal, Senate Republicans say the American Rescue Plan includes money for programs with little or no connection to the pandemic’s economic fallout. Chief among them is the $350 billion for states and local governments that GOP lawmakers say is nothing but a “blue state bailout” for jurisdictions that have been poorly managed by Democrats.
Sen. Susan Collins, R-Maine, one of the senators behind a $618 billion GOP counterproposal, said she doesn’t expect a single Republican to support the House bill, “even if we’re able to make some beneficial changes.”
“The administration has not indicated a willingness to come down from its $1.9 trillion figure, and that’s a major obstacle,” she said Tuesday.
The House bill also includes a controversial provision to increase the national hourly minimum wage from $7.25 to $15 by 2025 that proponents say is necessary to help the country recover economically but that opponents contend would force businesses to cut back.
Though a Pew Research poll found two-thirds of Americans back a $15 wage, Senate Republicans and at least two Democrats — Joe Manchin of West Virginia and Kyrsten Sinema of Arizona — oppose such an increase.
But a $15 federal minimum wage won’t make it into the final bill. A key Senate official on Thursday ruled the provision can’t even be included in the COVID package because it doesn’t qualify as a budgetary issue. That ruling makes it ineligible to be considered with the rest of the relief package under a budgetary process known as reconciliation where bills can be enacted with 51 votes instead of needing the 60 votes to overcome a filibuster.
With a minimum wage provision looking unachievable, Senate Democrats are seeking another way to raise hourly wages.
Senate Majority Leader Chuck Schumer, D-N.Y., was considering amending the relief package with a provision to penalize large corporations who did not pay their workers at least $15 per hour, according to a senior Democratic aide speaking on condition of anonymity, though the details of the provision were not yet available.
Any change in the Senate to the bill would delay relief because the measure would have to go back to the House.
Even if the minimum wage provision were removed from the bill, Pelosi said Friday the House would “absolutely” be able to pass the bill.
“We have a consensus in our caucus that we’re here to get the job done for the American people,” she said.
Read or Share this story: https://www.usatoday.com/story/news/politics/2021/02/26/joe-bidens-covid-relief-bill-stimulus-checks-passes-house/6836187002/